Technical Analysis for ATNM - Actinium Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 0.3899 -8.28% -0.04
ATNM closed down 8.28 percent on Monday, August 10, 2020, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical ATNM trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish -8.28%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center (MSKCC), a related institution. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213.
Chemistry Biopharmaceutical Cancer Physical Sciences Immunology Natural Sciences Antibodies Chemical Elements Stem Cells Acute Myeloid Leukemia Monoclonal Antibody Platform Technology Transplantation Actinides

Is ATNM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.649
52 Week Low 0.16
Average Volume 25,718,616
200-Day Moving Average 0.27
50-Day Moving Average 0.41
20-Day Moving Average 0.49
10-Day Moving Average 0.53
Average True Range 0.06
ADX 37.18
+DI 24.95
-DI 28.49
Chandelier Exit (Long, 3 ATRs ) 0.45
Chandelier Exit (Short, 3 ATRs ) 0.52
Upper Bollinger Band 0.67
Lower Bollinger Band 0.32
Percent B (%b) 0.21
BandWidth 71.54
MACD Line 0.02
MACD Signal Line 0.05
MACD Histogram -0.0216
Fundamentals Value
Market Cap 31.2 Million
Num Shares 80 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -0.75
Price-to-Sales 0.00
Price-to-Book 4.30
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.46
Resistance 3 (R3) 0.46 0.44 0.45
Resistance 2 (R2) 0.44 0.43 0.44 0.44
Resistance 1 (R1) 0.42 0.42 0.41 0.41 0.44
Pivot Point 0.40 0.40 0.39 0.40 0.40
Support 1 (S1) 0.37 0.38 0.36 0.37 0.34
Support 2 (S2) 0.35 0.37 0.35 0.34
Support 3 (S3) 0.33 0.35 0.33
Support 4 (S4) 0.32